Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclooxygenase-2 expression in chondrosarcoma.

Karen M Sutton1, Marianne Wright, Gertrud Fondren

  • 1Orthopedic Biological Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

Oncology
|June 26, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Gender Differences in Technical Skills and Confidence in Orthopaedic Surgery Residency Applicants.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews·2023
Same author

Shoulder and elbow pathology in the female athlete: sex-specific considerations.

Journal of shoulder and elbow surgery·2020
Same author

Sports Medicine Considerations During the COVID-19 Pandemic.

The American journal of sports medicine·2020
Same author

Five Myths of COVID-19 for the Team Physician.

HSS journal : the musculoskeletal journal of Hospital for Special Surgery·2020
Same author

Considerations for Return to Exercise Following Mild-to-Moderate COVID-19 in the Recreational Athlete.

HSS journal : the musculoskeletal journal of Hospital for Special Surgery·2020
Same author

Evaluation and Resuscitation of the Pregnant Orthopaedic Trauma Patient: Considerations for Maternal and Fetal Outcomes.

JBJS reviews·2019
Same journal

Real-World Outcomes in Acute Promyelocytic Leukemia: A 13-Year Cohort from Qatar.

Oncology·2026
Same journal

SF3A3 in Liver Hepatocellular Carcinoma: Oncogenic Role and Prognostic Significance.

Oncology·2026
Same journal

Letter to the Editor.

Oncology·2026
Same journal

FLAG-Based Versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.

Oncology·2026
Same journal

Longitudinal Changes in Body Weight and Body Mass Index in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Retrospective Observational Study.

Oncology·2026
Same journal

Rising lung cancer burden attributable to high fasting plasma glucose in women aged ≥50 years: age-, SDI-, and BRICS-specific patterns from GBD 1990-2021.

Oncology·2026
See all related articles

Cyclooxygenase-2 (COX-2) is present in chondrosarcoma but not enchondroma, suggesting a role in this cancer. Further research into COX-2 inhibitors for chondrosarcoma treatment is recommended.

Area of Science:

  • Oncology
  • Biochemistry

Background:

  • Tissue cyclooxygenase-2 (COX-2) is implicated in carcinogenesis and tumor malignancy.
  • COX-2 inhibitors show potential in managing carcinomas and sarcomas.

Purpose of the Study:

  • To investigate the presence of COX-2 in cartilage tumors.
  • To determine if COX-2 expression correlates with tumor type (enchondroma vs. chondrosarcoma).

Main Methods:

  • Western blot technique used to detect COX-2.
  • Analysis of 32 cartilage tumor samples (8 enchondromas, 21 chondrosarcomas).

Main Results:

  • COX-2 was detected in 13 of 24 chondrosarcoma samples.
  • COX-2 was not detected in any of the 8 enchondroma samples.

Related Experiment Videos

  • No statistically significant correlation found between COX-2 presence and clinical data.

    • Conclusions:

    • COX-2 appears to play a role in chondrosarcoma but not in benign enchondromas.
    • Further studies on COX-2 inhibitors for chondrosarcoma are warranted.